On Tuesday, Organon & Co (NYSE: OGN) opened higher 8.47% from the last session, before settling in for the closing price of $7.44. Price fluctuations for OGN have ranged from $6.18 to $17.23 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -23.49% over the past five years. Company’s average yearly earnings per share was noted -7.86% at the time writing. With a float of $258.95 million, this company’s outstanding shares have now reached $259.98 million.
Organon & Co (OGN) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Organon & Co is 0.40%, while institutional ownership is 77.99%. The most recent insider transaction that took place on Nov 12 ’25, was worth 501,755. In this transaction Executive Chair of this company bought 65,400 shares at a rate of $7.67, taking the stock ownership to the 77,869 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 12,469 for $8.07, making the entire transaction worth $100,591. This insider now owns 12,469 shares in total.
Organon & Co (OGN) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 0.9 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.87) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.52% during the next five years compared to -23.49% drop over the previous five years of trading.
Organon & Co (NYSE: OGN) Trading Performance Indicators
Check out the current performance indicators for Organon & Co (OGN). In the past quarter, the stock posted a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.33. Likewise, its price to free cash flow for the trailing twelve months is 2.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.92, a number that is poised to hit 0.76 in the next quarter and is forecasted to reach 3.96 in one year’s time.
Technical Analysis of Organon & Co (OGN)
Organon & Co (NYSE: OGN) saw its 5-day average volume 5.22 million, a negative change from its year-to-date volume of 6.11 million. As of the previous 9 days, the stock’s Stochastic %D was 77.93%.
During the past 100 days, Organon & Co’s (OGN) raw stochastic average was set at 36.99%, which indicates a significant decrease from 94.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.26 in the past 14 days, which was lower than the 0.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.21, while its 200-day Moving Average is $9.50. Nevertheless, the first resistance level for the watch stands at $8.34 in the near term. At $8.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.09. If the price goes on to break the first support level at $7.59, it is likely to go to the next support level at $7.12. Assuming the price breaks the second support level, the third support level stands at $6.84.
Organon & Co (NYSE: OGN) Key Stats
There are currently 259,983K shares outstanding in the company with a market cap of 2.10 billion. Presently, the company’s annual sales total 6,403 M according to its annual income of 864,000 K. Last quarter, the company’s sales amounted to 1,602 M and its income totaled 160,000 K.
